Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

AEterna's IND for Neoretna approved in Canada

June 16, 1997

Retinal protein reduces need for standard drugs in uveitis

June 10, 1997

Oculex and Storz sign marketing agreement for ocular product

June 5, 1997

Monarch acquires ocular therapy from Glaxo Wellcome

May 30, 1997

Alphagan introduced in the U.K.

May 29, 1997

Short-acting beta1-adrenoceptor blockers from U. of Melbourne

May 27, 1997

Update on PDT's Purlytin

May 23, 1997

Compounds with dual antiinflammatory/antioxidant activity from Alcon

May 8, 1997

Allergan claims prostaglandin derivatives with vasodilating activity

April 25, 1997

Senju describes new calpain inhibitor

April 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...